{"id":"AGY-FED-HEALTH-OTHER-014","kind":"order","level":"federal","jurisdiction":"United States (federal); Drug Enforcement Administration, Diversion Control Division (with SAMHSA)","state":"","metro":"","industry":"","agency":"FED-HEALTH-OTHER","eco":"","issuer":"Thomas W. Prevoznik, Deputy Assistant Administrator, Diversion Control Division, DEA","authority":"21 U.S.C. 802(54)(D), 823(g)(2); 21 C.F.R. 1301.28","instrument":"DEA-DC-022 (DEA068), letter permitting DATA-waived practitioners to prescribe buprenorphine to new patients on the basis of a telephone evaluation during the COVID-19 emergency","title":"DEA/SAMHSA Buprenorphine Telemedicine (Final)","dateIssued":"2020-03-31","effective":"2020-03-31","end":"Until the public health emergency declared by the Secretary ends, unless DEA specifies an earlier date (extended by 88 Fed. Reg. 30037)","startDate":"2020-03-31","endDate":"2021-09-30","quarters":["2020Q2","2020Q3","2020Q4","2021Q1","2021Q2","2021Q3"],"types":["HC","TELE","OTHER"],"addressees":["DATA-waived practitioners","opioid treatment programs"],"clause":"This additional flexibility under which authorized practitioners may prescribe buprenorphine to new patients on the basis of a telephone evaluation is in effect from March 31, 2020, until the public health emergency declared by the Secretary ends, unless DEA specifies an earlier date.","enforcement":"Prescriptions outside the allowance unlawful under 21 U.S.C. 829(e), 841-843","functions":["TM telehealth (audio-only induction)","CL clinical intake","CB patients"],"notes":"Reached behavioral-health and addiction-treatment providers, FQHCs and telehealth companies.","sourceUrl":"https://www.deadiversion.usdoj.gov/GDP/(DEA-DC-022)(DEA068)%20DEA%20SAMHSA%20buprenorphine%20telemedicine%20%20(Final)%20+Esign.pdf","snapshot":"","fileExists":true,"fileBytes":213521,"grade":"primary","character":"","description":"","collection":"AGY-FED-HEALTH-OTHER","url":"/library/AGY-FED-HEALTH-OTHER-014","exhibitUrl":"/exhibit/AGY-FED-HEALTH-OTHER-014","citation":"Thomas W. Prevoznik, Deputy Assistant Administrator, Diversion Control Division, DEA, DEA-DC-022 (DEA068), letter permitting DATA-waived practitioners to prescribe buprenorphine to new patients on the basis of a telephone evaluation during the COVID-19 emergency (Mar. 31, 2020) (Ex. AGY-FED-HEALTH-OTHER-014)","stateName":"","related":["AGY-FED-HEALTH-OTHER-011","AGY-FED-HEALTH-OTHER-016","AGY-FED-HEALTH-OTHER-010","AGY-FED-HEALTH-OTHER-020"]}